Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Recent studies in kidney transplant recipients with PTDM found that empagliflozin improves glycemic control and reduces body weight compared to the placebo group
This effect is intentional and evidence-based, supported by multiple clinical trials demonstrating its safety and efficacy
In a 12-week clinical trial, participants receiving 1mg per day of AOD-9604 lost an average of 2.6kg compared to 0.8kg in the placebo group
Current FDA-approved labeling includes both injectable Wegovy and oral Wegovy tablets
However, no further improvement was observed (Fig
US$ 21.25
US$ 25.82
US$ 29.62
US$ 22.47
US$ 22.53
